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Nuclear factor-B (NF-B) is an inducible transcrip-
tion factor central in the regulation of expression of a
wide variety of genes and synthesis of several proteins
involved in the generation of the immune response and
inflammatory processes. In resting cells, NF-B is main-
tained in an inactive state through cytoplasmic reten-
tion by IB inhibitors. Stimulation of cells with a wide
variety of inducers results in proteolytic degradation of
these IB proteins, leading to activation of NF-B. The
present study shows that interleukin-1 (IL-1) causes per-
sistent activation of NF-B in glial cells. Stimulation
with IL-1 also causes rapid but transient degradation of
IB- and IB-. However, NF-B remains active even
after these IB isoforms have returned to control levels.
In contrast, the IB- isoform fails to reappear following
its initial degradation by IL-1, coincident with sustained
activation of NF-B. In addition, in vivo overexpression
of the various IB isoforms revealed that IB- is the
only isoform that has the ability to inhibit IL-1-induced
NF-B-driven transcription. The findings also suggest
that the inability of IB- and IB- to modulate NF-B
activity is due to their modification in vivo. These find-
ings indicate that IB- is the key regulator of the ac-
tivity of NF-B in human glial cells.
Nuclear factor B (NF-B)1 is a transcription factor that is
employed in the inducible expression of a wide variety of cel-
lular genes, in particular those encoding immunoreceptors,
cytokines, and viral proteins (1, 2). NF-B exists in the cytosol
of resting cells as a homo- or heterodimer of proteins of the Rel
family of transcription factors. Each member of this family
contains a conserved N-terminal region called the Rel-homol-
ogy domain, which contains the DNA-binding domain, the
dimerization domain, and the nuclear localization signal (3). To
date, five Rel-related NF-B proteins have been identified in
mammalian cells: p65 (Rel A), Rel B, the proto-oncogene c-rel,
p50/p105, and p52/p100. The transcriptional activity of the Rel
proteins is tightly regulated by their association with members
of the inhibitory molecule family, IB (4). Several IB isoforms
have been identified, but the most extensively characterized
isoforms are IB-, IB-, and IB-. This family of proteins
share conserved motifs referred to as ankyrin repeats, which
are required for their association with the Rel homology region
of the NF-B proteins. This association has two functions.
First, IB sequesters NF-B in the cytosol by masking its
nuclear localization signal through direct protein-protein inter-
actions, and second, IB can prevent NF-B from binding to
DNA by masking its DNA-binding domain (5). Exposure of cells
to certain stimuli, e.g. the cytokines, IL-1 and tumor necrosis
factor or bacterial and viral products such as LPS, double-
stranded RNA, and the Tax protein from the human T-cell
leukemia virus 1, causes phosphorylation of IB on two specific
N-terminal serines: Ser-32 and Ser-36 on IB- (6, 7), Ser-19
and Ser-23 on IB- (8), and Ser-18 and Ser-22 on IB- (9).
Such signal-induced phosphorylation is believed to be carried
out by the newly discovered IB kinases (10–14) and repre-
sents a signal for ubiquitin conjugation of IB, followed by
degradation via the 26 S proteasome. This allows translocation
of active NF-B to the nucleus, where it binds to its consensus
sequences within the promoter regions of genes, thus activat-
ing transcription (15–17). In addition to the signal-induced
phosphorylation of the IBs, it has also been shown that sites
of constitutive phosphorylation exist within the C-terminal
PEST (proline-, glutamic acid-, serine- and threonine-rich) do-
mains of IB- and -, which affect intrinsic protein stability
(18–21). Casein kinase II has been shown to be responsible for
this phosphorylation, which occurs preferentially on Ser-293 in
IB- (20) and Ser-313 and Ser-315 in IB- (21). This casein
kinase II-mediated phosphorylation is required for efficient turn-
over of free IB- and IB- but is not involved in signal-induced
IB phosphorylation. The mechanism of degradation following
this basal phosphorylation has yet to be characterized.
Following stimulation, the nature of NF-B activation may
be transient or persistent, depending entirely on the cellular
stimulus. Tumor necrosis factor and phorbol 12-myristate 13-
acetate cause rapid but transient activation of NF-B (22).
Typically, activity peaks within 30 min, followed by a return to
basal activity within 4–6 h. In contrast, stimulation with IL-1,
LPS, or the human T-cell lymphotrophic virus 1 Tax protein
tends to result in long term persistent activation of NF-B,
which has been shown to last for up to 48 h (8, 22). Interest-
ingly, these studies reported that all stimuli of NF-B activa-
tion cause degradation of IB-, whereas IB- is only de-
graded by those inducers that cause long term persistent
activation of NF-B. Preliminary studies on the recently dis-
covered IB- indicate that this isoform may also be degraded by
all inducers of NF-B (9). Hence, it has been suggested that
differential patterns of degradation of the IB isoforms represent
an important mechanism in the regulation of NF-B activation.
Previous work has shown that NF-B activation is sustained
in glial cells in response to stimulation with IL-1 (23, 24).
However, the mechanistic basis for this persistent activation of
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NF-B was not resolved. This is of clinical relevance, because
the sustained activation of NF-B in brain cells may lead to
prolonged induction of leukocyte adhesion molecules and che-
mokines that will facilitate cerebral recruitment of leukocytes,
culminating in the generation of neuropathological states. The
purpose of this study was to examine the relative importance of
the IB isoforms (, , and ) in regulating the temporal acti-
vation of NF-B in glial cells. We show that prolonged disap-
pearance of IB- in response to IL-1 underlies concurrent
sustained activation of NF-B, and we provide direct evidence
for the first time that NF-B in glial cells is subject to selective
inactivation by the  form of the IB members.
EXPERIMENTAL PROCEDURES
Materials—The human astrocytoma cell line 1321N1 was obtained
from the European Collection of Animal Cell Cultures (Salisbury, UK).
DMEM, fetal calf serum, penicillin-streptomycin, and trypsin were from
Life Technologies, Inc. (Paisley, UK). Human rIL-1 was purchased
from R&D Systems Europe (Oxon, UK). T4 polynucleotide kinase, the
22-bp oligonucleotide containing the NF-B consensus sequence (un-
derlined) (5-AGTTGAGGGGACTTTCCCAGGC-3) were supplied by
Promega (Madison, WI). [-32P]ATP, [-32P]dATP, and nylon transfer
membranes were purchased from Amersham Pharmacia Biotech (Buck-
inghamshire, UK). Rabbit polyclonal antibodies against IB- and
IB- were obtained from Santa Cruz Biotechnologies (Santa Cruz,
CA). Affinity-purified rabbit polyclonal antiserum against IB- was a
gift from Nancy Rice (National Cancer Institute, Frederick Cancer
Research and Development Center, Frederick, MD). Sheep anti-rabbit
IgG peroxidase conjugate and the Enhanced Chemiluminescence detec-
tion system were purchased from Roche Molecular Biochemicals UK
Ltd. (East Sussex, UK). The pCMV4 vectors containing full-length
cDNA encoding IB- and IB- were generously provided by Dean
Ballard (Vanderbilt University, Nashville, TN). The pcDNA3-IB-
plasmid was generously provided by Simon T. Whiteside (Pasteur In-
stitute, Paris, France). The NF-B-luciferase reporter construct (con-
sisting of five tandem B sites cloned into the polylinker of pGL3 Basic
vector (Promega), the anti-p50, p65, and c-rel antisera and the polym-
erase chain reaction primers for -actin (exon 3 forward: 5-CGTAA-
CACTGGCATCGTG-3 and exon 4 reverse: 5-GTTTCGTGGATGCCA-
CAG-3) were generously provided by Luke O’Neill (Trinity College,
Dublin, Ireland). The C-terminal histidine-tagged recombinant forms of
IB-, IB-, and IB- were gifts from Jorg Eder (Novartis Pharma
AG, Switzerland) and have been described previously (25).
Cell Culture—The human astrocytoma cell line, 1321N1, was cul-
tured in DMEM supplemented with 100 units/ml penicillin, 100 g/ml
streptomycin, and 10% (v/v) of fetal calf serum. Cells were maintained
at 37 °C in a humidified atmosphere of 5% CO2. All cells were passaged
using 1% (w/v) of trypsin in DMEM. IL-1 stimulation was performed
on cells in serum-containing medium at 37 °C for all experiments.
Preparation of Subcellular Fractions—1321N1 astrocytoma were
seeded into 25-cm2 flasks (5 ml; 2  105 cells/ml) and allowed to adhere
for 72 h before stimulation. Cells were exposed to IL-1 for various
times. Stimulation was terminated by removal of medium followed by
washing of the adherent cells with 3 ml of ice-cold PBS. Washed cells
were scraped into 1 ml of hypotonic buffer (10 mM HEPES-NaOH
buffer, pH 7.9, containing 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, and
0.5 mM PMSF). Cells were pelleted in hypotonic buffer by centrifugation
at 21,000  g for 10 min and then lysed for 10 min on ice in hypotonic
buffer (35 l) containing 0.1% (v/v) of Nonidet P-40. Lysates were
centrifuged at 21,000  g for 10 min. The resulting supernatants
constituted cytosolic extracts and were removed to new Minifuge tubes
and stored at 20 °C. The resulting pellets were resuspended in 20 mM
HEPES-NaOH buffer, pH 7.9 (25 l), containing 420 mM NaCl, 1.5 mM
MgCl2, 0.2 mM EDTA, 25% (w/v) glycerol, and 0.5 mM phenylmethyl-
sulfonyl fluoride and incubated for 15 min on ice. Incubations were then
centrifuged at 21,000  g for 10 min, and the supernatants were
transferred to 10 mM HEPES/NaOH buffer, pH 7.9 (75 l), containing
50 mM KCl, 0.2 mM EDTA, 20% (w/v) glycerol, 0.5 mM phenylmethyl-
sulfonyl fluoride, and 0.5 mM DTT. Such samples constituted nuclear
extracts. Protein concentrations of the cytosolic and nuclear extracts
were determined by the method of Bradford (26). All of the above steps
were carried out at 4 °C.
Electrophoretic Mobility Shift Assay—Nuclear extracts (4–10 g of
protein) were incubated with 20,000 dpm of a 22-bp oligonucleotide
containing the NF-B consensus sequence, which previously had been
labeled with [-32P]ATP (10 mCi/mmol) by T4 polynucleotide kinase
(27). Incubations were performed for 30 min at room temperature in 10
mM Tris-HCl buffer, pH 7.5, containing 100 mM NaCl, 1 mM EDTA, 5
mM DTT, 4% (w/v) glycerol, 4 g of poly(dI-dC), and 1 mg/ml nuclease-
free BSA. In the supershift analysis, polyclonal antisera (1 l) against
the NF-B subunits p65, p50, p52, and c-rel were added to the extracts
and incubated for 30 min on ice prior to incubation with labeled oligo-
nucleotide. IB-, IB-, and IB- were examined for their modulation
of the DNA binding activity of NF-B by incubating the extracts in the
absence and presence of recombinant forms of IB (1 g) for 30 min at
room temperature prior to incubation with labeled oligonucleotide. All
incubations were subjected to electrophoresis on 4% non-denaturing poly-
acrylamide gels that were subsequently dried and autoradiographed.
Western Immunoblotting—Cytosolic extracts (20 g of protein) were
boiled in an equal volume of 2 sample buffer for 5 min prior to loading.
2 sample buffer consisted of 0.125 M Tris-HCl buffer, pH 6.8, containing
20% (w/v) glycerol, 4% (w/v) SDS, 1.4 M 2--mercaptoethanol, and
0.0025% (w/v) bromphenol blue. The extracts and biotinylated molecular
mass markers (14–100 kDa) were separated by SDS-PAGE using a 12%
(w/v) resolving gel. The proteins were transferred electrophoretically to
nitrocellulose and blocked by overnight incubation at room temperature
in 20 mM Tris-HCl buffer, pH 7.5, containing 0.5 M NaCl (TBS) and 5%
(w/v) powdered milk (Marvel). The blots were washed three times (10 min
each) in TBS containing 0.05% (v/v) Tween 20 (TTBS) and then incubated
for 2 h with primary polyclonal antibody against IB- or IB- (1 g/ml)
or antiserum against IB- (1:2000) diluted in TTBS containing 1% (w/v)
powdered milk (Marvel). The blots were subsequently washed in TTBS
before incubation for 45 min with horseradish-peroxidase-conjugated
sheep anti-rabbit IgG (1:1000 dilution) and horseradish-peroxidase-con-
jugated streptavidin (1:5000 dilution). The blots were washed, and immu-
noreactive bands were detected using the Enhanced Chemiluminescence
detection system from Roche Molecular Biochemicals (Germany) accord-
ing to the instructions of the manufacturer.
Northern Blot Analysis—Total RNA was extracted from cells by
guanidinium thiocyanate and isolated as described previously (28).
Total RNA (12 g per sample) was separated by 1% (w/v) formaldehyde-
agarose gel electrophoresis and transferred overnight onto nylon mem-
branes by capillary action. The RNA was cross-linked to the membranes
by exposing to 120,000 J/cm2 for 30 s within the Stratagene Stratal-
inker UV cross-linker. The membranes were incubated at 42 °C for 15
min in a solution containing 50% (v/v) formamide, 5 SSC, 5 Den-
hardt’s solution, 1% (w/v) SDS, and 100 g/ml salmon sperm DNA.
Radiolabeling of IB-, IB-, IB-, and human -actin cDNA probes
was achieved by nick translation with [-32P]dATP using Escherichia
coli DNA polymerase I and DNase I (28). The probes were added to the
hybridization solution at a concentration of 10 ng/ml, and hybridization
was carried out overnight at 42 °C with rotation. The membranes were
washed twice with 2 SSC containing 0.1% (w/v) SDS and twice with
0.2 SSC containing 0.1% (w/v) SDS at room temperature (low strin-
gency). Two further washes were carried out using 0.2 SSC/0.1% (w/v)
SDS at 42 °C (medium stringency), followed by two final washes with
0.1 SSC/0.1% (w/v) SDS at 68 °C (high stringency). High stringency
washes were carried out on the IB-, IB-, and -actin blots. IB-
was detected under medium stringency conditions. The blots were then
rinsed in 2 SSC, covered in UV-transparent wrap, and autoradio-
graphed at 70 °C for 72 h.
Transient Transfections—The pCMV4-IB-, pCMV4-IB-, and
pcDNA3-IB- constructs were described previously (8, 9). For control
transfections, the empty pCMV4 vector was used. Human 1321N1
astrocytoma were seeded at 1  105 cells/ml and allowed to grow until
confluent. Cells were trypsinized, and 1  107 cells were transfected by
electroporation (using the Invitrogen Electroporator II) with 3 g of
NF-B luciferase construct and 6 g of either pCMV4, pCMV4-IB-,
pCMV4-IB-, or pcDNA3-IB-. As an internal control for transfec-
tion efficiency, 2 g of pHook--gal plasmid was co-transfected for all
experiments. Aliquots (3 ml) of cells were then seeded into 6-well plates
(4  105 cells/well), and the cells were incubated at 37 °C in a humid-
ified atmosphere of 5% CO2 for 48 h. Cells were then treated with or
without IL-1 (10 ng/ml), and cellular extracts were prepared 12 h later
using reporter lysis buffer (Promega). Extracts were centrifuged at
21,000  g for 10 min, and the supernatants were analyzed for lucifer-
ase and -galactosidase activity using kits from Promega and Strat-
agene, respectively, according to the instructions of the manufacturers.
RESULTS
IL-1 Causes Rapid and Persistent Activation of NF-B in
Glial Cells—Nuclear extracts were prepared from unstimu-
lated and IL-1-treated human 1321N1 astrocytoma and as-
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sayed for NF-B activity by EMSA (Fig. 1). Trace levels of basal
NF-B activation were apparent in the form of faint
DNAprotein complexes in extracts from unstimulated cells.
Rapid and sustained activation of NF-B was observed in re-
sponse to stimulation with IL-1 and was represented as the
appearance of a NF-BDNA complex of slow electrophoretic
mobility. NF-B activity was detectable after 5-min stimula-
tion and remained for at least 72 h. Unbound radioactive probe
migrated freely through the gel and appeared as a dark band at
the bottom of the gel. The subunit composition of the NF-B
complexes induced by IL-1 was investigated by incubating nu-
clear extracts from IL-1-stimulated cells with antisera against
p50, p65, p52, or c-rel and observing the effects on the electro-
phoretic mobility of the NF-BDNA complexes (Fig. 1B). IL-1-
induced complexes were unaffected by pretreatment with anti-
c-rel, p52, and the non-immune IgG isotype control. In contrast,
anti-p65 caused a reduction in the levels of the IL-1-induced
complexes with the concomitant appearance of two super-
shifted complexes of slow electrophoretic mobility. The anti-
p50 antibody also caused a reduction in the levels of the IL-1-
induced complexes, albeit not to the same extent as the anti-
p65 antibody, with the associated appearance of a single
supershifted complex. The latter shows a similar mobility to
the faster moving supershifted complex using anti-p65, sug-
gesting that it consists of a p50p65 heterodimeric complex. The
supershifted complex of slowest electrophoretic mobility, using
the anti-p65 antibody, is not formed by the other antibody, thus
suggesting that this complex represents a p65p65 homodimer.
This would indicate that the IL-1-induced NF-B complexes
consist primarily of p50p65 and p65p65 dimers. Because the
levels of NF-B are controlled by the IB isoforms, it was decided
to probe the effects of IL-1 in relation to the levels of the three IB
isoforms (, , and ) in an attempt to explain the underlying
mechanisms to sustained activation of NF-B in these cells.
IL-1 Causes Rapid Degradation but Subsequent Resynthesis
of IB-—Cytosolic extracts were prepared from unstimulated
and IL-1-treated human 1321N1 astrocytoma and assessed
for IB- protein levels byWestern blot analysis (Fig. 2A). High
levels of IB- were detectable in cytosolic extracts from un-
stimulated cells. IB- was rapidly degraded upon stimulation
with IL-1 and was undetectable in the cytosol after only 5 min
of stimulation. This degradation was transient because the
level of IB- returned to basal values after 1 h and remained
at this level for up to 72 h. To characterize the mechanism of
the transient degradation, the levels of mRNA encoding IB-
were measured after IL-1 treatment.
FIG. 1. Rapid and persistent activation of NF-B in 1321N1
astrocytoma cells in response to IL-1. 1321N1 astrocytoma were
seeded at 2 105 cells/ml and grown to confluency. A, cells were treated
in the absence (upper panel) and presence (lower panel) of IL-1 (10
ng/ml) for the indicated time periods. Control cells were treated with
vehicle (PBS/0.1% (w/v) BSA). Nuclear extracts (4 g of protein) were
assayed for NF-BDNA binding activity by EMSA as described under
“Experimental Procedures.” B, 1321N1 cells were incubated in the
absence or presence of IL-1 (10 ng/ml) for 1 h, after which nuclear
extracts were prepared and assessed for NF-B binding activity in the
absence and presence of polyclonal antisera against the NF-B subunits
p50, p65, p52, and c-rel. Non-immune IgG was used as a control. The
arrows indicate the mobility of unbound oligonucleotide (Free Probe),
the specific NF-BDNA complexes activated by IL-1, and basal NF-
BDNA complexes. The arrowheads indicate the mobilities of the su-
pershifted complexes. These results are representative of three inde-
pendent experiments.
FIG. 2. Rapid degradation and subsequent resynthesis of
IB- in response to IL-1. 1321N1 astrocytoma were seeded at 2 
105 cells/ml and grown to confluency. Cells were then treated with IL-1
(10 ng/ml) for the indicated time periods. Control cells (C) were treated
with vehicle (PBS/0.1% (w/v) BSA). A, cytosolic extracts (20 g of
protein) were subjected to SDS-PAGE and probed by Western immu-
noblotting with anti-human IB- antibody. Proteins were visualized
by enhanced chemiluminescence. The electrophoretic mobility of molec-
ular mass markers are indicated. B, total RNA extracts were prepared
and 12 g of RNA subjected to 1% (w/v) agarose electrophoresis, blotted
onto nylon membrane, and probed with a radiolabeled probe comple-
mentary to IB- mRNA (upper panel). The nylon was then stripped
and probed for -actin mRNA (lower panel). These results are repre-
sentative of three independent experiments.
IB- in Glial Cells39998
 at M
aynooth U
niversity on July 18, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Total RNA extracts were prepared from unstimulated and
IL-1-treated human 1321N1 astrocytoma and assessed for
IB- mRNA levels by Northern blot analysis (Fig. 2B). A very
low level of IB- mRNA expression was detectable in extracts
from unstimulated cells. The expression of IB- mRNA was
rapidly up-regulated within 30 min of IL-1 treatment and
reached peak levels by 1 h. This up-regulation was sustained
because levels remained elevated for at least 24 h. These find-
ings are consistent with the rapid reappearance of the IB-
protein in the cytosol of these cells, as detected by Western
immunoblotting. The same blot was then reprobed for the
housekeeping gene, -actin. As expected, IL-1 had no effect on
the expression of -actin mRNA. The transient disappearance
of IB- did not correlate with the sustained activation of
NF-B, suggesting that the other forms of IB may be more
important in regulating NF-B. The regulation of IB- by IL-1
was next examined.
IL-1 Causes Sustained Degradation and Fails to Resynthe-
size IB-—Cytosolic extracts were prepared from unstimu-
lated and IL-1-treated cells and assessed for IB- protein
levels by Western immunoblotting (Fig. 3A). High levels of
IB- were detectable in cytosolic extracts from unstimulated
cells. IB- was degraded more slowly than IB- upon stim-
ulation with IL-1; high levels of IB- remained detectable in
the cytosol after 5 min of stimulation. However, by 30 min of
stimulation, IB- was undetectable. In contrast to IB-,
IB- degradation was sustained, because the levels remained
undetectable over most of the time points for up to 72 h. The
mechanism of regulation of IB- was next assessed by char-
acterizing the regulation of mRNA levels of IB- by IL-1.
Total RNA extracts were prepared from unstimulated and
IL-1-treated cells and assessed for IB- mRNA levels by
Northern blot analysis (Fig. 3B). A low level of IB- mRNA
expression was detectable in extracts from unstimulated cells.
In contrast to IB- mRNA expression, the expression of IB-
mRNA did not change from basal levels upon stimulation with
IL-1. However the prolonged disappearance of IB- protein in
response to IL-1 indicates that translation of IB- may be
blocked or that IL-1 causes its continuous degradation. The
sustained disappearance of IB- correlates well with pro-
longed activation of NF-B, suggesting a crucial role for IB-
in regulating NF-B in glial cells. However, the relative role of
IB- remained to be determined.
IL-1 Causes Degradation but Subsequent Resynthesis of IB-
—Cytosolic extracts were prepared from unstimulated and
IL-1-treated cells and assessed for IB- protein levels by
Western blot analysis (Fig. 4A). High levels of IB- were
detectable in cytosolic extracts from unstimulated cells. IB-
was degraded more slowly than IB- in response to IL-1; IB-
remained detectable in the cytosol after 5- and 30-min stimu-
FIG. 3. IL-1 causes sustained degradation and fails to resyn-
thesize IB-. 1321N1 astrocytoma were seeded at 2  105 cells/ml
and grown to confluency. Cells were then treated with IL-1 (10 ng/ml)
for the indicated time periods. Control cells (C) were treated with
vehicle (PBS/0.1% (w/v) BSA). A, cytosolic extracts (20 g of protein)
were subjected to SDS-PAGE and probed by Western immunoblotting
with anti-human IB- antibody. Proteins were visualized by enhanced
chemiluminescence. The electrophoretic mobility of molecular mass
markers are indicated. B, total RNA extracts were prepared and 12 g
of RNA subjected to 1% (w/v) agarose electrophoresis, blotted onto nylon
membrane, and probed with a radiolabeled probe complementary to
IB-mRNA (upper panel). The nylon was then stripped and probed for
-actin mRNA (lower panel). These results are representative of three
independent experiments.
FIG. 4. Degradation and subsequent resynthesis of IB- in
response to IL-1. 1321N1 astrocytoma were seeded at 2  105 cells/ml
and grown to confluency. Cells were then treated with IL-1 (10 ng/ml)
for the indicated time periods. Control cells (C) were treated with
vehicle (PBS/0.1% (w/v) BSA). A, cytosolic extracts (20 g of protein)
were subjected to SDS-PAGE and probed by Western immunoblotting
with anti-human IB- antibody. Proteins were visualized by enhanced
chemiluminescence. The electrophoretic mobility of molecular mass
markers are indicated. B, total RNA extracts were prepared and 12 g
of RNA subjected to 1% (w/v) agarose electrophoresis, blotted onto nylon
membrane, and probed with a radiolabeled probe complementary to
IB-mRNA (upper panel). The nylon was then stripped and probed for
-actin mRNA (lower panel). These results are representative of three
independent experiments.
IB- in Glial Cells 39999
 at M
aynooth U
niversity on July 18, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
lation. However, similar to IB-, IB- degradation was tran-
sient. The amount of IB- returned to basal levels after 3 h of
stimulation and remained at this level up to 72 h. Again, the
basis of this resynthesis was assessed at the level of mRNA.
Total RNA extracts were prepared from unstimulated and
IL-1-treated cells and assessed for IB- mRNA levels by
Northern blot analysis (Fig. 4B). A very low level of IB-
mRNA expression was detectable in extracts from unstimu-
lated cells. The expression of IB- mRNA was up-regulated
upon stimulation with IL-1 and reached peak levels by 3 h.
These findings are consistent with the rapid reappearance of
the IB- protein in the cytosol of these cells, as detected by
Western blot. These findings suggest circumstantially that the
IB- isoform is the crucial form in controlling the activity
status of NF-B in glial cells. However, the reappearance of
IB- and - with no coincident reduction in NF-B levels
questions the role, if any, of these isoforms in controlling the
activity of NF-B in glial cells. To examine directly the relative
contributions of each of the IB isoforms in controlling NF-B,
genes encoding the three forms were cotransfected with a NF-
B-regulated reporter gene and examined for their inhibitory
potential on the induction of the reporter gene.
In Vivo Overexpression of the IB Isoforms—1321N1 astro-
cytoma were transfected with the various expression vectors
for the IB isoforms, and the resulting cell lysates were ana-
lyzed for expression of the respective proteins by Western blot
analysis (Fig. 5A). Lane 1 corresponds to cells transfected with
empty pCMV4 vector, and no IB proteins were detectable in
these extracts. It must be noted that these extracts contained
considerably less protein than those in Figs. 2A, 3A, and 4A, in
which 20 g of protein had been loaded per lane compared with
0.2 g in this case. This explains why endogenous levels of the
IB isoforms were undetectable in these blots. Lanes 2, 3, and 4,
corresponding to cells transfected with expression vectors encod-
ing IB-, IB-, and IB-, respectively, show high levels of the
respective IB isoforms. This experiment confirms that the trans-
fected plasmids are being expressed efficiently in vivo.
Overexpression of IB- Inhibits Transactivation by NF-B—
1321N1 astrocytoma were co-transfected with the plasmids
containing cDNAs encoding the various IB proteins and a
B-dependent luciferase reporter gene and were subsequently
stimulated in the absence and presence of IL-1. Cells lysates
were then prepared and analyzed for luciferase activity (Fig.
5B). In the presence of empty pCMV4 vector, IL-1 strongly
induced transcription of the reporter gene (an 11-fold induction
over control). IL-1 induced similar levels of luciferase expres-
sion in the presence of co-transfected IB- or IB-. Therefore,
expression of IB- or IB- had no effect on B-dependent
transcription induced by IL-1. In contrast, cotransfection with
IB- resulted in significant inhibition of IL-1-induced tran-
scription of the luciferase reporter construct. This experiment
demonstrates that IB- is the only IB isoform capable of
inhibiting the transactivation activity of NF-B in 1321N1
astrocytoma.
Recombinant IB Isoforms Inhibit the in Vitro DNA Binding
Activity of NF-B—The inability of overexpressed IB- and
IB- to inhibit the transactivation of NF-B coupled to the
earlier findings showing that the activation of NF-B was
sustained even in the presence of newly synthesized IB- and
IB- prompted an investigation into their lack of inhibitory
potential. The modification of the NF-B complexes or IB-
and IB- were plausible alternative proposals for the lack of
inhibition. To resolve these alternative mechanisms the ability
of recombinant forms of the three IB proteins were assessed
for their in vitro ability to inhibit the DNA binding activity of
the sustained complexes, which were activated by IL-1 in
1321N1 astrocytoma. Thus nuclear extracts were generated
from cells that had been stimulated with IL-1 for 48 h. The
extracts were examined for NF-B activity by EMSA in the
absence and presence of C-terminal histidine-tagged recombi-
nant forms of IB-, IB-, and IB- (25). IL-1 caused the
typical activation of two NF-B complexes of slow electro-
phoretic mobility. Intriguingly, IB- and IB- blocked the
DNA binding activity of both complexes, whereas IB- only
inhibited the complex of slowest mobility. This strongly op-
poses the in vivo inhibitory effects of the overexpressed IB
isoforms where the opposite inhibitory profile was observed.
The ability of IB- and IB- to inhibit the DNA binding of the
NF-B complexes contrasts with their lack of effect when over-
FIG. 5. Overexpression of IB- inhibits transactivation by
NF-B. 1321N1 astrocytoma (1  107 cells) were transfected with 3 g
of NF-B-luciferase reporter construct and 2 g of a CMV-driven -gal
reporter construct. In addition to these constructs, the cells were trans-
fected with 6 g of one of the following: empty pCMV4 vector (pCMV4),
pCMV4 containing IB- (pCMV4-IB-), pCMV4 containing IB-
(pCMV4-IB-), or pcDNA3 containing IB- (pcDNA3-IB-). The
cells were allowed to recover for 48 h before stimulation with or without
(C) IL-1 (10 ng/ml) for a further 12 h. A, cell lysates were analyzed for
the expression of the IB proteins by Western immunoblotting. Lysates
(0.2 g of protein) were subjected to SDS-PAGE, electrophoretically
transferred to nitrocellulose, and probed with anti-human IB- (upper
panel), anti-mouse IB- (middle panel), and anti-human IB- (lower
panel) polyclonal antibodies. The figure shows extracts from cells trans-
fected with: empty vector pCMV4 (lane 1), pCMV4-IB- (lane 2),
pCMV4-IB- (lane 3), and pcDNA3-IB- (lane 4). The electro-
phoretic mobility of molecular mass markers is also shown. B, cell
lysates were analyzed for luciferase and -galactosidase activity. The
results are expressed as luciferase activity/-gal activity and represent
the mean  S.E. (n  4) for a representative experiment. A repeat of
this experiment gave a similar finding. Statistical analysis was carried
out using an unpaired Student t test (*** denotes a p value of 0.0001).
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expressed in vivo. This strongly suggests that, in the in vivo
environment, IB- and IB- proteins are modified in some
manner that abolishes their inhibitory potential.
DISCUSSION
The regulation of NF-B activation by the IB isoforms has
recently become an area of intensive research in many cell
types. The present study probes the molecular nature of this
control in glial cells. This is of much importance, because the
activation of NF-B in brain cells will lead to the induction of
pro-inflammatory genes resulting in cerebral inflammation.
Indeed, one of the authors has previously reported that IL-1
activates NF-B and induces sustained expression of leukocyte
adhesion molecules in glial cells (23, 24). This may underlie
leukocyte accumulation, which is a prologue to neuropathology.
The temporal regulation of NF-B by IL-1 in glial cells is
addressed in the present study, and the relative importance of
the various IB isoforms in regulating NF-B activity is also
evaluated.
IL-1 caused rapid and sustained activation of NF-B in
human 1321N1 astrocytoma. This confirms previous studies in
this laboratory, which have shown IL-1 to activate NF-B for
up to 24 h in rat and human glial cells (23, 24). It is also
consistent with studies in other cells types, such as B- and
T-cells, in which sustained activation of NF-B by IL-1 was also
observed (8, 22). This persistent activation of NF-B prompted
an investigation of the mechanisms underlying the regulation
of NF-B in these cells concentrating specifically on the role of
the different IB isoforms.
The effect of IL-1 on the intracellular levels of IB was
initially assessed. IB- was observed to be rapidly and com-
pletely degraded upon stimulation with IL-1. However, degra-
dation was only transient, because control levels of the protein
were detectable within 1 h of IL-1 stimulation. This rapid
reappearance of IB- is due to increased transcription of the
gene encoding IB-, because Northern analysis showed sig-
nificant increases in the levels of IB- mRNA with a time
profile corresponding closely to the reappearance of the protein.
In addition, transcriptional up-regulation continued for up to
24 h thus ensuring that high IB- levels were maintained in
the cell. These results are consistent with previous studies,
which indicate that IB- regulates NF-B through a novel
autoregulatory feedback loop (29–34). Although this model ex-
plains the activation of NF-B by agents that cause transient
activation, it fails to explain the persistent activation of NF-B,
observed in response to IL-1 stimulation in the present study.
It appears that IB- is unable to shut down the NF-B re-
sponse in this case, because NF-B remains fully active even
after cellular IB- levels have returned to normal. It was
apparent from this observation that IB- was not the sole
regulator of NF-B activation in response to IL-1, which led to
examination of the second IB isoform, IB-.
IB- shares many common properties with IB-. Both
isoforms interact with the same spectrum of Rel proteins with
equal affinity, resulting in the inhibition of both nuclear local-
ization and DNA binding ability of NF-B (5). Upon stimula-
tion, both proteins become phosphorylated on similarly located
N-terminal serines and are subsequently degraded by the ubiq-
uitin/proteasome pathway (35). The present study demon-
strated that IL-1 induced IB- degradation in glial cells, ac-
companied by persistent long term activation of NF-B.
Degradation of IB- occurred with slightly slower kinetics
than IB-, which is in agreement with previous observations
in B- and T-cells (8, 22). Once phosphorylated, IB is quickly
ubiquitinated and degraded. Thus, the efficiency of phospho-
rylation dictates how rapidly IB degradation occurs. IB- has
been shown to be a less-efficient substrate for the IB kinase
subunits when compared with IB-, therefore, it has been
proposed that the slower rate of degradation of IB-, is due to
a slower rate of phosphorylation (10, 11).
Unlike IB-, the degradation of IB- was not followed by
its resynthesis. As already outlined, the rapid reappearance of
the IB- protein is due to NF-B-directed up-regulation of the
IB- gene. Although the cis-acting elements that regulate the
IB- gene remain undefined, recent reports suggest that this
transcriptional unit is not under NF-B control (8, 22). Indeed,
this was confirmed in the present study with the observation
that IB- mRNA transcription was unaffected by stimulation
with IL-1. These findings establish a strong correlation be-
tween the chronic down-regulation of IB- protein expression
and the failure of IL-1 to induce IB- gene transcription. The
slow but persistent degradation of IB- observed in response
to IL-1 stimulation in these cells suggests that IB- may not
be utilized for regulating rapid responses but may respond to
persistent signals that yield a more permanent change.
The third isoform of IB to be examined in this study was the
recently discovered, IB- (9, 36). IB- is similar in structure
to IB- and IB-, containing multiple ankyrin repeats and
two conserved serine residues, which are necessary for degra-
dation of the protein by the ubiquitin/proteasome pathway.
However, in this study IB- displayed its own unique pattern
of degradation in response to IL-1 stimulation. IB- was de-
graded in 1321N1 astrocytoma with relatively slow kinetics, a
characteristic shared with IB-. But like IB-, IB- was
rapidly resynthesized, returning to control levels by 3 h after
IL-1 stimulation. This was explained by findings from North-
ern analysis, which showed strong up-regulation of IB-
mRNA transcription upon stimulation with IL-1. The short
period of time between degradation and resynthesis indicates
that, like IB-, IB- is tightly regulated in these cells. Whi-
teside et al. (9) reported similar kinetics for the degradation of
IB- in Jurkat cells in response to LPS. This group proposed
FIG. 6. IB- and IB- but not IB- inhibit the DNA binding
activity of sustained NF-B complexes. 1321N1 astrocytoma were
seeded at 2  105 cells/ml and grown to confluency. Cells were treated
in the absence (C) and presence of IL-1 (10 ng/ml) for 48 h, after which
nuclear extracts were prepared and assessed for NF-B binding activity
in the absence and presence of C-terminal histidine-tagged recombi-
nant forms of IB-, IB-, or IB- (1 g). The arrows indicate the
mobility of unbound oligonucleotide (Free Probe) and NF-BDNA com-
plexes activated by IL-1. These results are representative of three
independent experiments.
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that IB- could control a third type of NF-B response: Those
that are slow but still transient in nature.
The kinetics of degradation and resynthesis of the various
IB isoforms observed in this study suggests that the inability
of NF-B to up-regulate transcription of the IB- gene tran-
scription is the key to the persistent activation of NF-B in glial
cells. It appears that the resulting long term down-regulation
of IB- protein synthesis allows NF-B released from NF-
BIB- complexes to remain fully active for long periods of
time. However, this can only be achieved if the NF-B released
from IB- is resistant to the newly synthesized IB- and
IB-. In B-cells, such resistance is achieved by association of
NF-B with a modified form of IB- (37). The initial degrada-
tion of IB- in B-cells in response to stimulation with LPS is
followed by resynthesis of the protein in a hypophosphorylated
form. This newly synthesized IB- associates with free NF-
B, preventing it from interacting with IB-. Unlike basally
phosphorylated IB-, unphosphorylated IB- is unable to
mask the nuclear localization signal or DNA-binding domains
of NF-B. Therefore, the NF-B bound to unphosphorylated
IB- can still enter the nucleus and remains transcriptionally
active. Due to its association with hypophosphorylated IB-,
NF-B is resistant to inhibition by IB-, allowing it to remain
persistently active. However, the present study demonstrates
that IB- is degraded and is not resynthesized even in the
hypophosphorylated form in glial cells, suggesting a novel reg-
ulatory mechanism. Interestingly, the inability of the recombi-
nant form of IB- to inhibit in vitro the DNA binding activity
of one of the IL-1-activated NF-B complexes is likely due to its
unphosphorylated state. This is further discussed below.
Previous studies had also suggested that when NF-B is
released from IB-, it may become modified, conferring resist-
ance to inhibition by IB- and IB- (22). To determine
whether activated NF-B is modified in such a way as to affect
its interactions with the IB proteins in glial cells, the present
study went on to investigate the effects of overexpression of the
IB isoforms on IL-1-induced NF-B-driven transcription.
High levels of the various IB isoforms were detected in lysates
from transfected cells. Interestingly, the overexpression of
IB- or IB- had no effect on the strong induction of the
NF-B-luciferase gene observed upon stimulation with IL-1. In
contrast, IB- significantly inhibited this induction. This im-
plies that the p50p65 subunits driving the expression of the
reporter gene are only susceptible to inhibition by IB-. The
fact that IB- expression is chronically down-regulated follow-
ing IL-1 stimulation explains why NF-B remains active for
long periods of time. The mechanism underlying the inability of
overexpressed IB- or IB- to modulate the transactivation
potential of NF-B was finally explored. Such lack of inhibition
could be explained by modification of the NF-B complexes to
states that would make them refractory to inhibition by the two
IB isoforms. Alternatively, the IB proteins may be subject to
their own modification, which may reduce their inhibitory po-
tential. This was directly addressed by probing the in vitro
inhibitory effects of recombinant forms of the IB proteins on
the DNA binding activity of the sustained NF-B complexes.
The recombinant forms represent the unmodified state and
would allow for resolution of the mechanism. The strong in
vitro inhibitory effects of the recombinant IB- and IB-
contrast with their lack of influence on the in vivo expression of
a NF-B-regulated reporter gene. This strongly suggests that
IB- and IB- proteins are modified in 1321N1 astrocytoma
to states that are ineffectual in modulating NF-B. IB- was
less effective in inhibiting the in vitro DNA binding activity of
the sustained NF-B complexes. However, this is likely due to
its hypophosphorylated state, whereas its capacity to strongly
reduce the induction of the NF-B-regulated reporter gene is
presumably due to basal phosphorylation of IB- in the cells.
The inhibition of the NF-B-regulated reporter gene by IB- is
incomplete suggesting additional regulatory mechanisms that
are independent of IB-, IB-, and IB-.
In summary, it has been demonstrated that IL-1 causes long
term, persistent activation of NF-B in glial cells. Although the
breakdown of IB- and IB- may be involved in the initial
transient phases of activation, the prolonged degradation of
IB- may be the key step in mediating persistent NF-B
activation in these cells. Knowledge of this system may be
exploited in the development of novel therapeutic agents, and
the above findings immediately suggest IB- as a suitable
target for an anti-inflammatory regime in glial cells.
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